Track Record

We have done business with AstraZeneca UK Limited, AstraZeneca Netherlands, and AstraZeneca Global.

We worked on the following products:

• cediranib (Recentin®)
• gefitinib (Iressa®)
• olaparib (Lynparza®)
• acalabrutinib (Calquence)

We worked together on the following projects:

• 2009: In collaboration with AstraZeneca UK Limited we provided strategic advise during the Advisory Board in Gastric Cancer, Manchester, UK.
• 2011: In collaboration with AstraZeneca Netherlands, we reviewed the gefitinib brochure for Healthcare Professionals.
• 2011: In collaboration with AstraZeneca Netherlands, we organized a meeting at several locations throughout the Netherlands: “Management of side effects of EGFR tyrosine kinase inhibitors-associated adverse events in lung cancer.” Together with a local pulmonologist in several locations throughout The Netherlands.
• 2011: In collaboration with AstraZeneca Netherlands, we provided strategic advice during the Advisory Board patient-related documentation about gefitinib (Iressa®).
• 2017: In collaboration with AstraZeneca Netherlands, we organized a training session for nurses on the management of immuno-oncology and targeted therapy-associated adverse events.
• 2017: In collaboration with AstraZeneca Netherlands, we updated the patient gefitinib brochure.
• 2019: In collaboration with AstraZeneca Global and MSD Global, we trained oncologists from around the globe during the Olaparib Breast Cancer Speaker Forum on how to run an effective patient consultation with Olaparib patients.
• 2020: We helped AstraZeneca Netherlands prepare documentation for acalabrutinib with an adjusted version of CMSI Kickstart.

We have done business with  Baxalta International

We worked on the following products:

• nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) for metastatic pancreatic cancer.

We worked together on the following projects:

• 2016: In collaboration with Baxalta International, we provided strategic advice during the International European Advisory Board Meeting about nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Vienna, Austria.

We have done business with  Bayer Global, Bayer Europe, Middle East & Africa, and  Bayer Netherlands.

We worked on the following products:

• sorafenib (Nexavar®) is a kinase inhibitor used in treating hepatocellular carcinoma, renal cell carcinoma, and certain types of thyroid cancer.
• regorafenib (Stivarga®)

We worked together on the following projects:

• 2012/2013: In collaboration with Bayer Netherlands, we provided strategic advice during the Consultative Group Meetings sorafenib. Development of materials for healthcare professionals & patients.
• 2013: In collaboration with Bayer Region Europe/Canada, we developed a Slide desk for regorafenib-associated adverse events
• 2013: In collaboration with Bayer Region Europe/Canada, we trained European nurses (Train-the-Trainer) in one day about “Regorafenib-associated adverse event management,” Berlin, Germany
• 2013: In collaboration with Bayer Netherlands, we trained nurses and physicians about “Regorafenib-associated adverse events” in several locations throughout The Netherlands.
• 2014: In collaboration with Bayer Global and Cor2Ed, we developed an Educational Programme with ESMO on multikinase inhibitors and their dermatological side effects. This independent medical education program is supported by an independent educational grant from Bayer HealthCare. You can consult the Oncology-PRO here.
• 2014: In collaboration with Bayer Netherlands, we trained nurses at the Netherlands Cancer Institute on targeted therapy-associated adverse event management.
• 2015: In collaboration with Bayer Global and conjunction with prIME Oncology, we recorded “prIME Oncology’s Expert Review in Dermatologic Toxicities of Targeted Agents in Metastatic CRC: Anticipating, Communicating, and Managing These Events.“

We have done business with Becton, Dickinson & Company (BD) UK.

We worked on the following products:

• BD PhaSeal™ closed system transfer device for hazardous drug handling.

We worked together on the following project:

• 2016: In collaboration with BD UK, we provided strategic advice during the “Roundtable: How safe do you feel in the administration of hazardous drugs?“ Amsterdam, The Netherlands. Results were published at: http://www.hospitalpharmacyeurope.com/

We have done business with Boehringer Ingelheim Netherlands and  Boehringer Ingelheim European Regional Operating Unit. 

We worked on the following products:

• nintedanib (Vargatef®)
• afatinib (Giotrif®)

We worked together on the following projects:

• 2013: In collaboration with Boehringer Ingelheim Netherlands, we provided in-company training about afatinib-associated mucocutaneous adverse events at the headquarters of Boehringer Ingelheim Netherlands in Alkmaar, The Netherlands.
• 2015: In collaboration with Boehringer Ingelheim Netherlands, we provided an in-company Safety Profile Boot Camp about TKI-associated adverse events at Boehringer Ingelheim Netherlands' headquarters in Alkmaar, The Netherlands.
• 2015: In collaboration with Boehringer Ingelheim Netherlands, we reviewed and edited the afatinib kit for healthcare professionals.
• 2015/2016: In collaboration with Boehringer Ingelheim Netherlands, we trained pulmonologists, pharmacists, and nurses about “Adverse event management in the use of targeted therapies and angiogenesis inhibitors” in several locations throughout The Netherlands:

01-12-2015: Rotterdam

08-12-2015: Groningen

22-12-2015: Eindhoven

12-01-2016: Amsterdam

14-01-2016: Ulvenhout

26-01-2016: Zwolle

28-01-2016: Den Haag

04-02-2016: Vught

16-02-2016: Hengelo

24-05-2016: Groningen

05-07-2016: Amersfoort

07-07-2016: Rotterdam

06-09-2016: Nijmegen

08-09-2016: Arnhem

18-10-2016: Arnhem

• 2016: In collaboration with Boehringer Ingelheim Netherlands, we recorded a video series in Dutch for physicians about selected afatinib-associated adverse events: paronychia, maculopapular rash, oral complaints, and mushy stool and diarrhea. 
• 2016: In collaboration with Boehringer Ingelheim Netherlands, we trained pulmonologists and nurse specialists on “Developments in Lung Cancer—Meet the Expert.” Duiven, The Netherlands.
• 2016: In collaboration with Boehringer Ingelheim European Regional Operating Unit, we recorded a video series in English for internal training about selected nintedanib-associated adverse events: diarrhea, nausea, vomiting, loss of appetite, neutropenia, and increased liver enzymes.

We have done business with BMS Netherlands.

We worked on the following products:

• nivolumab (Opdivo®)

We worked together on the following project:

• 2016: In collaboration with BMS Netherlands, we developed treatment guidelines about the management options for immune-related adverse events and patient information about nivolumab (Opdivo®).

We have done business with  EUSA Pharma UK Ltd.

We worked on the following products:

• supersaturated calcium-phosphate rinse (Caphosol®), a topical oral agent, is a US-patented medical device that lubricates the mucosa of the mouth, tongue, and oropharynx and helps maintain the integrity of the oral cavity through its mineralizing potential. The distinguishing feature of Caphosol® is its high concentrations of calcium and phosphate ions.
• tivozanib, an oral, once-daily vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective, and long half-life inhibitor of all three VEGF receptors. It is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been investigated in several tumor types, including renal cell, colorectal, and breast cancers. EUSA Pharma submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC) in March 2016.

We worked together on the following projects:

• 2012/2016 In collaboration with EUSA Pharma UK Ltd, we worked on the Investigator Initiated COMTT trial. Eusa is an independent co-sponsor.
• 2016: In collaboration with EUSA Pharma UK Ltd, we provided in-company training about “Tivozanib—Adverse Event Management following the steps of the TARGET system.”

We have done business with Galera Therapeutics Global.

We worked on the following products:

• GC4419 is a first-in-class, small molecule enzyme mimetic that converts superoxide to hydrogen peroxide and molecular oxygen. GC4419 is currently being evaluated in an ongoing randomized Phase 2 clinical trial to assess its effect on the incidence, severity, and duration of severe oral mucositis (OM) when given to patients with squamous cell cancers of the head and neck in combination with radiation and chemotherapy. GC4419 previously completed a Phase 1b/2a clinical trial, and results were presented at the 2016 Annual Meeting of the American Society of Radiation Oncology (ASTRO). In this study, compared to historical controls, GC4419 appeared to:

•    Decrease severe OM incidence (WHO Grade 3+4)

•    Delay severe OM onset

•    Shorten severe OM duration

•    Lessen significant radiation therapy treatment breaks

GC4419 was generally safe and well tolerated. Some patients experienced mild facial paresthesia. There was no evidence of tumor protection, and the mechanism of action is thought to favor increasing tumor radiation response. GC4419 has received fast-track designations from the U.S. Food and Drug Administration.

We worked together on the following project:

• 2017: In collaboration with Galera Therapeutics Global, we provided strategic advice during the Advisory Board about the treatment of radiation-induced mucositis in Barcelona, Spain.

We have done business with GSK Netherlands.

We worked on the following products:

• lapatinib (Tykerb® (USA); Tyverb® (EU)), an orally active drug for patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2) and other solid tumors.

We worked together on the following projects:

• 2008: In collaboration with GSK Netherlands, we provided strategic advice during the Expert Panel Member Meeting at Lapatinib in Utrecht, The Netherlands.
• 2011: In collaboration with GSK Netherlands, we reviewed and edited patient-related material regarding lapatinib.
• 2011: In collaboration with GSK Netherlands, we provided in-company training about adverse event management TKIs, with special attention to GSK’s lapatinib and pazopanib.
• 2012/2013: In collaboration with GSK Netherlands, we provided Assessment training for mucocutaneous adverse events at several locations throughout The Netherlands.

We have done business with Helsinn Global.

We worked on the following products:

• netupitant (Netu; NKE; R 1124; Ro 67-3189/000) for pruritus

We worked together on the following project:

• 2016: In collaboration with Helsinn Global, we provided strategic advice during the “Helsinn Pruritus in Cancer Patients - International Multidisciplinary Experts Panel” in Zurich, Switzerland

We have done business with  Ipsen Global.

We worked on the following products:

• cabozantinib (Cabometyx®) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

We worked together on the following projects:

• 2017: In collaboration with Ipsen Global, we provided strategic advice during the “Optimising Patient Management Strategies in RCC: What Nurses Need to Know”  for Medscape Oncology” Amsterdam, The Netherlands

to be added.

We have done business with Lifestream Pharma NV SA In conjunction with Caresse Cosmetics. 

We worked on the following products:

• lactoperoxidase (BioXtra) dry mouth ultra-mild mouth rinse. BioXtra® provides four interrelated oral care products specially formulated to moisturize, comfort, protect the mouth, and promote better oral hygiene. Reference. Lactoperoxidase is a peroxidase enzyme secreted from mammary, salivary, and other mucosal glands that functions as a natural antibacterial agent. Lactoperoxidase is a member of the heme peroxidase family of enzymes. In humans, lactoperoxidase is encoded by the LPO gene. Lactoperoxidase catalyzes the oxidation of a number of inorganic and organic substrates by hydrogen peroxide. These substrates include bromide and iodide; therefore, lactoperoxidase can be categorized as a haloperoxidase. Another important substrate is thiocyanate. The oxidized products produced through the action of this enzyme have potent bactericidal activities. Lactoperoxidase, together with its inorganic ion substrates, hydrogen peroxide, and oxidized products, is known as the lactoperoxidase system. The lactoperoxidase system plays an important role in the innate immune system by killing bacteria in milk and mucosal (linings of mostly endodermal origin, covered in epithelium, which are involved in absorption and secretion) secretions hence augmentation of the lactoperoxidase system may have therapeutic applications. Furthermore, the addition or augmentation of the lactoperoxidase system has potential applications in controlling bacteria in food and consumer health care products. The lactoperoxidase system does not attack DNA and is not mutagenic. However, the lactoperoxidase system may contribute to oxidative stress under certain conditions. Furthermore, lactoperoxidase may contribute to the initiation of breast cancer through its ability to oxidize estrogenic hormones, producing free radical intermediates.

BioXtra Dry Mouth Ultra Mild Mouth rinse gently supplements natural saliva by regulating the microenvironment of the mouth. The mild-tasting formulation strengthens enamel, helps fight against the formation of dental caries, and eases the symptoms and effects of Dry Mouth (xerostomia). It helps maintain the mouth’s natural balance and cleanses, refreshes, and lubricates it. BioXtra Dry Mouth Ultra Mild Mouth rinse is alcohol- and menthol-free.

We worked together on the following project:

• 2016/2017: In collaboration with Lifestream Pharma nv sa, we trained nurses and physicians on using various kinds of products within immuno-oncology and targeted therapy treatment.

We have done business with  Merck Netherlands.

We worked on the following products:

• cetuximab (Erbitux®)
•  vitamin K1 cream

We worked together on the following projects:

• 2006: In collaboration with Merck Netherlands, we developed patient information/Fact sheets for treatment with cetuximab: dry skin, fissures, papulopustular rash, and paronychia.
• 2012: In collaboration with Merck Netherlands, we provided strategic advice on Vitamin K to the Scientific Advisory Board.
• 2012: In collaboration with Merck Netherlands, we trained nurses on cetuximab-associated rash and Vitamin K cream.
• 2014: In collaboration with Merck Netherlands, we developed the research protocol and protocol-associated documentation for the ProSkin study—a prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: ProSkin Netherlands.
• 2014: In collaboration with Merck Netherlands, we trained nurses on cetuximab-associated skin reaction management.
• 2015: In collaboration with Merck Netherlands, we developed documentation for healthcare professionals on skin reactions during treatment with cetuximab (Erbitux®).
• 2015: In collaboration with Merck Netherlands, we recorded a video for the Merck Family & Board about the long-standing partnership with Merck Netherlands.

We have done business with MSD Global, MSD Europe, and  MSD Austria.

We worked on the following products:

• ridaforolimus (also known as AP23573 and MK-8669; formerly known as deforolimus), an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression, and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma.

We worked together on the following projects:

• 2011: In collaboration with MSD Global, we provided strategic advice during the Global Oral Stomatitis Expert Input Forum in Lisbon, Portugal
• 2012: In collaboration with MSD Global, we provided strategic advice during the Jenzyl EU Train the Trainer in Lisbon, Portugal
• 2012: In collaboration with MSD Europe, we provided strategic advice during the Expert Meeting Stomatitis, Munich, Germany

We have done business with Nordic Pharma Netherlands.

We worked on the following products:

• tegafur, gimeracil and oteracil (Teysuno®). It is available as capsules containing 15 mg tegafur with 4.35 mg gimeracil and 11.8 mg oteracil, and capsules containing 20 mg tegafur with 5.8 mg gimeracil and 15.8 mg oteracil. Teysuno is used to treat adults with advanced gastric (stomach) cancer. It is used in combination with cisplatin. Tegafur is a ‘prodrug’ that is converted in the body to a chemical called 5-fluorouracil (5-FU). 5-FU is similar to pyrimidine, a substance found in the genetic material of cells (DNA and RNA). In the body, 5-FU takes the place of pyrimidine and interferes with the enzymes involved in making new DNA. As a result, it prevents the growth of cancer cells and eventually kills them. The two other active substances in Teysuno allow tegafur to be effective at lower doses and with fewer side effects: gimeracil by preventing the breakdown of 5-FU and oteracil by reducing the activity of 5-FU in normal, non-cancerous tissue in the gut.

We worked together on the following projects:

• 2014/2015: In collaboration with Nordic Pharma Netherlands: Training about the differences between hand-foot syndrome, hand-foot skin reaction, and peripheral neuropathy. In conjunction with a local medical oncologist in several locations throughout The Netherlands.
• 2017: In collaboration with Nordic Pharma Netherlands, Training about the differences between hand-foot syndrome, hand-foot skin reaction, peripheral neuropathy, and poorly treated feet was conducted in conjunction with a local medical oncologist at several locations throughout The Netherlands.

We have done business with  Novartis Global, Novartis Netherlands,  Novartis Italy, and  Novartis Belgium.

We worked on the following products:

• everolimus (Afinitor, Zortress, Afinitor Disperz®), an mTOR inhibitor/selective immunosuppressant, is used in the treatment of brain tumors, breast cancer, neuroendocrine carcinoma, organ transplant, rejection prophylaxis, pancreatic cancer, renal angiomyolipoma, renal cell carcinoma, subependymal giant cell astrocytoma, and tuberous sclerosis.

We worked together on the following projects:

• 2008: In collaboration with Novartis Netherlands, we provided strategic advice during the Round Table input everolimus. Utrecht, The Netherlands.
• 2013: In collaboration with Novartis Global, we provided strategic advice during the Advisory Board for Afinitor, Educational Needs, Chicago, USA.
• 2013: In collaboration with Novartis Global, we provided strategic advice during the Novartis Oncology Leader's Summit 2013. The annual events focus on addressing unmet educational needs and fostering a collaborative multidisciplinary approach to breast cancer treatment. This year, the latest advances in the management of hormone receptor-positive and/or HER2-positive advanced breast cancer. Multidisciplinary Centers for Excellence. Geneva, Switzerland.
• 2014: In collaboration with Novartis Italy and in conjunction with COPE-unlimited, we trained nurses at a satellite symposium on “Recent advances in oral targeted therapies in patients with solid tumors” in Istanbul, Turkey.
• 2014: In collaboration with Novartis Netherlands and Eurocept Homecare, we trained homecare nurses about “Metastatic breast cancer patients treated with everolimus.” Arnhem, The Netherlands.
• 2015: In collaboration with Novartis Netherlands, we trained nurse practitioners in a masterclass during the annual conference for nurse practitioners, “Master Scientific Research in Oncology.” Papendal, The Netherlands.
• 2015: In collaboration with Novartis Global, we developed the Afinitor Video Project, an online education module for the nurses-only program.
• 2016: In collaboration with Novartis Belgium, we trained medical oncologists and their team in an interdisciplinary workshop on adverse event management. Oostkamp, Belgium.
• 2017: In collaboration with Novartis Belgium, we trained medical oncologists and their teams in an interdisciplinary workshop on Adverse Event Management in Brugge, Belgium.

We have done business with Pfizer Netherlands and Pfizer International Operations (S.A.S.) Medical Oncology Europe.

We worked on the following products:

• sunitinib (Sutent®)
• axitinib (Inlyta®)

We worked together on the following projects:

• 2009: In collaboration with Pfizer Netherlands, we trained physicians and nurses on therapy management while treating metastatic renal cell carcinoma with targeted therapy. Chair. Amsterdam, The Netherlands.
• 2011: In collaboration with Pfizer Netherlands and Curavista Health, we built a platform for patients with RCC: an online patient self-management diary designed for renal cell carcinoma patients.
• 2012: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe: We updated the president of Pfizer Europe and his team on “Therapy Management Needs, Personalized Needs, Projects, Interdisciplinary Multinational Collaboration in Past, Now and Future. Amsterdam, The Netherlands.
• 2013: We reviewed and edited the Patient information axitinib (Inlyta®) in collaboration with Pfizer Netherlands.
• 2014: In collaboration with Pfizer Netherlands, we recorded videos in Dutch for nurses and physicians about dermatological and oral assessment.
• 2014: In collaboration with Pfizer Netherlands, we developed an Online Education Module with a pre-and post-test for the face-to-face training “targeted therapy-associated mucocutaneous adverse events.” This pre- and post-test allowed participants to assess their knowledge progress.
• 2015: In collaboration with Pfizer Netherlands, we trained nurses in Therapy Management during sunitinib Treatment. Amsterdam, The Netherlands
• 2015: In collaboration with Pfizer Netherlands, we developed and provided a one-day (8-hour) in-depth training about targeted therapy-associated mucocutaneous adverse events for nurses and pharmacists in several locations throughout The Netherlands.
• 2016: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe, we provided strategic advice during the 3rd Onco Nurse Academy in Copenhagen, Denmark. Nurses from BeNeLux, the Nordic and Baltic region, and Belarus attended.
• 2016: In collaboration with Pfizer Netherlands, we developed and provided the interdisciplinary training “Management of targeted- & immunotherapy-associated skin, oral & mucosal reactions. Medical oncologists, pulmonologists, dermatologists, pharmacists, and nurse specialists attended the training and discussed during the training how to implement the effective adverse event approach in their daily practice. As an additional service, attendees received aftercare to support the implementation of the learned approach in day-to-day practice.
• 2017: In collaboration with Pfizer Netherlands, we developed and provided Immuno-Oncology Training of 3 hours together with a local physician (medical oncologist or pulmonologist)
• 2017: In collaboration with Pfizer International Operations (S.A.S.) Medical Oncology Europe, we provided strategic advice during the 4th Onco Nurse Academy. Copenhagen, Denmark.

will follow soon

We have done business with Takeda Global and Takeda Netherlands.

We worked on the following products:

• fentanyl (Instanyl®). Instanyl is a nasal spray that contains the active substance fentanyl (50, 100, and 200 micrograms per dose). It is available in single-dose containers and multidose containers. Instanyl is used to treat ‘breakthrough’ pain in adults with cancer. ‘Breakthrough pain’ is when a patient experiences additional, sudden pain despite ongoing treatment with painkillers. Instanyl is used in patients who are already using opioids to control long-term cancer pain.

We worked together on the following projects:

• 2014: In collaboration with Takeda Netherlands, we provided strategic advice during the Interdisciplinary Advisory Oral Pain Management Forum
• 2014: In collaboration with Takeda Netherlands, we provided in-house training in oral pain management.
• 2014: In collaboration with Takeda Global, we presented at the Meet-the-Experts session during the 8th EAPC World Research Congress, Lleida, Spain. Title of the presentation: Dry mouth and swallowing issues in cancer patients on targeted therapies
• 2014: In collaboration with Takeda Netherlands, we trained homecare nurses about targeted therapy-associated oral complaints in several locations throughout The Netherlands.

Are you interested in Dr. Christine Boers-Doets's approach, and do you want to work with Dr. Christine, too?

Then contact us at team@cancer-med.com